UY36759A - Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo - Google Patents

Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo

Info

Publication number
UY36759A
UY36759A UY0001036759A UY36759A UY36759A UY 36759 A UY36759 A UY 36759A UY 0001036759 A UY0001036759 A UY 0001036759A UY 36759 A UY36759 A UY 36759A UY 36759 A UY36759 A UY 36759A
Authority
UY
Uruguay
Prior art keywords
derivative
conjugate
glucagón
composition
same
Prior art date
Application number
UY0001036759A
Other languages
English (en)
Inventor
Lee Jong Suk
Lee Jong Min
Park Young Jin
Lim Chang Ki
Jung Sung Youb
Kwon Se Chang
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of UY36759A publication Critical patent/UY36759A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2264Obesity-gene products, e.g. leptin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2278Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un derivado de glucagón, a un conjugado de acción prolongada del derivado de glucagón y a un uso del mismo.
UY0001036759A 2015-06-30 2016-06-29 Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo UY36759A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20150093265 2015-06-30

Publications (1)

Publication Number Publication Date
UY36759A true UY36759A (es) 2017-01-31

Family

ID=57608802

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036759A UY36759A (es) 2015-06-30 2016-06-29 Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo

Country Status (32)

Country Link
US (3) US10696725B2 (es)
EP (2) EP3322437B1 (es)
JP (3) JP6882210B2 (es)
KR (2) KR102005456B1 (es)
CN (1) CN108025041A (es)
AR (1) AR105485A1 (es)
AU (2) AU2016287209B2 (es)
BR (1) BR112017028517A2 (es)
CA (1) CA2991107A1 (es)
CL (5) CL2017003402A1 (es)
CO (1) CO2018000303A2 (es)
CR (1) CR20180034A (es)
DK (1) DK3322437T5 (es)
DO (1) DOP2017000318A (es)
EA (1) EA201890058A1 (es)
EC (1) ECSP18003879A (es)
ES (1) ES2973017T3 (es)
FI (1) FI3322437T3 (es)
HK (1) HK1248129A1 (es)
HU (1) HUE066226T2 (es)
IL (2) IL256619B (es)
MA (2) MA41887B1 (es)
MX (1) MX2017016845A (es)
PE (2) PE20240215A1 (es)
PH (1) PH12017502393A1 (es)
PL (1) PL3322437T3 (es)
PT (1) PT3322437T (es)
TN (1) TN2017000555A1 (es)
TW (1) TWI713541B (es)
UA (1) UA127445C2 (es)
UY (1) UY36759A (es)
WO (1) WO2017003191A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
US11135271B2 (en) * 2014-12-30 2021-10-05 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
EP3322437B1 (en) 2015-06-30 2024-01-17 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
BR112018013525A2 (pt) 2015-12-31 2018-12-04 Hanmi Pharm. Co., Ltd. conjugado de longa atuação de agonista de receptor de glucagon/glp-1/gip triplo e composição farmacêutica
SG11201811697SA (en) 2016-06-29 2019-01-30 Hanmi Pharmaceutical Co Ltd Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
KR102645064B1 (ko) * 2017-02-03 2024-03-08 한미약품 주식회사 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도
KR20180091773A (ko) 2017-02-07 2018-08-16 한미약품 주식회사 비펩티드성 중합체 링커 화합물, 그 링커 화합물을 포함하는 결합체, 및 이들의 제조방법
KR20190038456A (ko) * 2017-09-29 2019-04-08 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체
WO2020017919A1 (ko) * 2018-07-19 2020-01-23 한미정밀화학주식회사 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
WO2020017916A1 (en) 2018-07-19 2020-01-23 D&D Pharmatech Inc. Pharmaceutical composition comprising polypeptide
KR101990075B1 (ko) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
BR112021006477A2 (pt) * 2018-10-04 2021-07-13 Hanmi Pharm. Co., Ltd. combinação que compreende uma substância com atividade para um receptor de glucagon ou um conjugado do mesmo, kit e composição farmacêutica para prevenir ou tratar doenças
CN109239346B (zh) * 2018-10-31 2019-10-11 中国药科大学 一组代谢标志物在代谢综合征早期诊断方面的应用
WO2020130751A1 (ko) 2018-12-21 2020-06-25 한미약품 주식회사 인슐린 및 글루카곤을 포함하는 약학 조성물
DK3936142T3 (da) * 2019-06-28 2024-03-25 Hanmi Pharmaceutical Co Ltd Tredobbelt agonist med aktivitet med hensyn til alle glucagon-, GLP-1- og GLP-receptorer til behandling af leversygdom
EP4043026A4 (en) * 2019-10-04 2024-01-10 Hanmi Pharm. Co., Ltd. GLUCAGON, GLP-1 RECEPTOR AND DGIP RECEPTOR DUAL AGONIST COMPOSITION AND THERAPEUTIC USE THEREOF
CN112898406B (zh) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
US20210290732A1 (en) * 2020-02-21 2021-09-23 Spitfire Pharma Llc GLP-1R and GCGR Agonists, Formulations, and Methods of Use
KR20210144606A (ko) 2020-05-22 2021-11-30 한미약품 주식회사 글루카곤 유도체의 지속형 결합체의 액상 제제
CN116096397A (zh) 2020-07-15 2023-05-09 韩美药品株式会社 胰高血糖素衍生物或其缀合物对于肝脏疾病的治疗用途
CA3188884A1 (en) * 2020-08-14 2022-02-17 Seungjae Baek Hypotensive pharmaceutical composition comprising triple activator having activity for all of glucagon, glp-1, and gip receptors
BR112023019917A2 (pt) 2021-04-09 2023-11-14 Hanmi Pharm Ind Co Ltd Uso de uma composição farmacêutica
KR20230095666A (ko) 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
US7576050B2 (en) 2001-07-31 2009-08-18 The United States Of America As Represented By The Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
MXPA05009940A (es) 2003-03-19 2005-12-05 Lilly Co Eli Compuestos de glp-1 de enlace de glicol polietilenico.
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
WO2005047334A1 (en) * 2003-11-13 2005-05-26 Hanmi Pharmaceutical. Co., Ltd. Igg fc fragment for a drug carrier and method for the preparation thereof
JP5297817B2 (ja) * 2006-02-22 2013-09-25 メルク・シャープ・アンド・ドーム・コーポレーション オキシントモジュリン誘導体
US8288339B2 (en) 2006-04-20 2012-10-16 Amgen Inc. GLP-1 compounds
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
RU2477286C2 (ru) 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
US7994122B2 (en) 2007-06-15 2011-08-09 Zealand Pharma A/S Glucagon analogues
CA2696615A1 (en) 2007-06-19 2008-12-24 Otsuka Chemical Co., Ltd. Oligosaccharide chain added glp-1 peptide
US8895694B2 (en) 2007-09-05 2014-11-25 Novo Nordisk A/S Glucagon-Like Peptide-1 derivatives and their pharmaceutical use
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
JP5753779B2 (ja) * 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation 生理学的pHの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
EP2300035B1 (en) 2008-06-17 2015-08-12 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
CL2009001424A1 (es) 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso.
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
SG176858A1 (en) 2009-06-16 2012-02-28 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds
ES2537287T3 (es) * 2009-07-13 2015-06-05 Zealand Pharma A/S Análogos de glucagón acilados
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US20130157953A1 (en) 2010-01-20 2013-06-20 Zealand Pharma A/S Treatment of cardiac conditions
JP6054861B2 (ja) 2010-03-26 2016-12-27 ノヴォ ノルディスク アー/エス 新規のグルカゴン類似体
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Gタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN103458920B (zh) 2010-12-22 2016-07-06 印第安那大学科技研究公司 表现出gip受体活性的胰高血糖素类似物
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
CN103732617A (zh) 2011-05-18 2014-04-16 梅德瑞斯糖尿病有限责任公司 用于胰岛素抵抗的改进的肽医药
EP3434687B1 (en) * 2011-06-10 2021-03-10 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
CN109306015B (zh) 2011-06-17 2022-04-26 韩美科学株式会社 包括泌酸调节肽和免疫球蛋白片段的结合物以及其应用
EP2729493B1 (en) 2011-07-04 2020-06-10 IP2IPO Innovations Limited Novel compounds and their effects on feeding behaviour
MX2014003579A (es) 2011-11-17 2015-04-10 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor de glucocorticoide.
WO2013120022A2 (en) 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
CN112142855A (zh) 2012-05-18 2020-12-29 爱德迪安(北京)生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
CA2877127A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogs of glucagon exhibiting gip receptor activity
RU2015101697A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
CA2890324C (en) * 2012-11-06 2021-02-23 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
US10005817B2 (en) 2012-11-20 2018-06-26 Eumederis Pharmaceuticals, Inc. Peptide pharmaceuticals
JP6525456B2 (ja) 2012-11-20 2019-06-05 メデリス ダイアビーティーズ,エルエルシー インスリン抵抗性のための改善されたペプチド製剤
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
AU2014255608B2 (en) 2013-04-18 2018-01-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US20160185837A1 (en) 2013-08-16 2016-06-30 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
JP6572497B2 (ja) 2013-12-18 2019-09-11 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、ステープル留めされたペプチド脂質複合体、及びそれらの組成物
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
EP3206710B1 (en) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Incretin-insulin conjugates
WO2016077806A1 (en) * 2014-11-13 2016-05-19 AskGene Pharma, Inc. Fusion proteins with dual receptor agonist activities
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
US11135271B2 (en) * 2014-12-30 2021-10-05 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
EP3322437B1 (en) 2015-06-30 2024-01-17 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
US20170004368A1 (en) 2015-07-05 2017-01-05 Neteera Technologies Ltd. System and method for biometric detection based on sweat ducts
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Fc區之蛋白質接合物
EP3384935A4 (en) 2015-12-02 2019-08-21 Hanmi Pharm. Co., Ltd. PROTEIN COMPLEX UTILIZING A FATTY ACID DERIVATIVE, AND PROCESS FOR PREPARING THE SAME
BR112018013525A2 (pt) 2015-12-31 2018-12-04 Hanmi Pharm. Co., Ltd. conjugado de longa atuação de agonista de receptor de glucagon/glp-1/gip triplo e composição farmacêutica

Also Published As

Publication number Publication date
IL256619A (en) 2018-04-30
US20200223897A1 (en) 2020-07-16
WO2017003191A1 (en) 2017-01-05
US20220127325A1 (en) 2022-04-28
DK3322437T5 (da) 2024-10-07
EA201890058A1 (ru) 2018-07-31
PE20180449A1 (es) 2018-03-05
AU2016287209A1 (en) 2018-02-15
KR20190092343A (ko) 2019-08-07
EP3322437A1 (en) 2018-05-23
IL291291A (en) 2022-05-01
KR102395855B1 (ko) 2022-05-10
HK1248129A1 (zh) 2018-10-12
PL3322437T3 (pl) 2024-05-20
CO2018000303A2 (es) 2018-07-10
EP3322437A4 (en) 2019-10-09
PE20240215A1 (es) 2024-02-16
PH12017502393A1 (en) 2018-06-25
TWI713541B (zh) 2020-12-21
US11667688B2 (en) 2023-06-06
JP2021102618A (ja) 2021-07-15
EP4324519A3 (en) 2024-07-24
US11261227B2 (en) 2022-03-01
AU2016287209B2 (en) 2023-03-02
FI3322437T3 (fi) 2024-02-20
TN2017000555A1 (en) 2019-04-12
AR105485A1 (es) 2017-10-11
CL2023001911A1 (es) 2023-11-17
EP4324519A2 (en) 2024-02-21
JP2018526333A (ja) 2018-09-13
US20180186853A1 (en) 2018-07-05
AU2023201118A1 (en) 2023-04-20
JP2023062043A (ja) 2023-05-02
CN108025041A (zh) 2018-05-11
KR20170003466A (ko) 2017-01-09
US10696725B2 (en) 2020-06-30
JP6882210B2 (ja) 2021-06-02
DK3322437T3 (da) 2024-03-25
MX2017016845A (es) 2018-08-01
MA41887B1 (fr) 2020-05-29
HUE066226T2 (hu) 2024-07-28
CL2017003402A1 (es) 2018-04-20
CR20180034A (es) 2018-04-16
CA2991107A1 (en) 2017-01-05
MA49545A1 (fr) 2021-09-30
PT3322437T (pt) 2024-03-20
MA41887A1 (fr) 2018-12-31
BR112017028517A2 (pt) 2018-08-28
IL256619B (en) 2022-04-01
DOP2017000318A (es) 2018-04-30
ECSP18003879A (es) 2018-03-31
IL291291B2 (en) 2023-06-01
NZ739250A (en) 2024-02-23
MA49545B1 (fr) 2022-03-31
TW201713681A (zh) 2017-04-16
EP3322437B1 (en) 2024-01-17
CL2023000198A1 (es) 2023-06-30
UA127445C2 (uk) 2023-08-30
KR102005456B1 (ko) 2019-07-30
ES2973017T3 (es) 2024-06-18
CL2023001909A1 (es) 2023-11-17
CL2023001910A1 (es) 2023-11-17

Similar Documents

Publication Publication Date Title
CL2023001911A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
CO2018005525A2 (es) Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab
CL2016002772A1 (es) Composiciones de insulina de rápida acción
ECSP18007905A (es) Anticuerpos monoclonales contra bcma
CL2016002455A1 (es) Anticuerpos multiespecíficos.
CR20160419A (es) Nuevos compuestos biciclicos
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
GT201600185A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
TR201910057T4 (tr) Kauçuk bi̇leşi̇mleri̇
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
GT201600252A (es) Derivados de naftiridinadiona
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
TR201901516T4 (tr) Nöroprotektif ajanlar ve bunların kullanımları.
BR112017024126A2 (pt) composições farmacêuticas e uso das mesmas
EA201692569A1 (ru) Полимиксины с низкой степенью замещения и композиции, их содержащие
CL2018000308A1 (es) Composiciones en microcápsulas que comprenden pirimetanilo
CL2023000971A1 (es) Esteroides y conjugados de proteínas de los mismos.
TR201402168A2 (tr) Tirozin kinaz baskılamaya yönelik oluşturulmuş, anti-inflamatuar etki gösteren bileşenler ihtiva eden bir kompozisyon.
PL411685A1 (pl) Koniugat i jego zastosowanie
UA114708U (uk) Тяговий привід електробуса
TR201402553A2 (tr) Hipolipidemik nitelik sergileyen sentetik protobiosid türevleri içeren bir kompozisyon.